Shares ofBolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro.
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today's mid-day session.
Gainers
- AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged 201% to $8.16.
Login or create a forever free account to read this news
Sign up/Log in